Abstract
BackgroundSo far, few have concerned miR-497-5p in lung squamous cell carcinoma (LUSC).MethodsMiR-497-5p expression in LUSC was measured by qRT-PCR. Its impacts on tumor-related cell behaviors were investigated by CCK8 assay, scratch healing assay, flow cytometry and Transwell invasion methods. In addition, interaction between miR-497-5p and CDCA4 in LUSC was also elucidated through rescue experiment, western blot, dual-luciferase, and bioinformatics analysis.ResultsLow level of miR-497-5p was confirmed in LUSC tissue and cells. Overexpressed miR-497-5p markedly inhibited cancer progression. miR-497-5p restrained CDCA4 expression. Rescue assay showed that overexpressing miR-497-5p eliminated effect of overexpressed CDCA4.ConclusionBy targeting CDCA4, miR-497-5p restrained development of LUSC.
Highlights
Few have concerned miR-497-5p in lung squamous cell carcinoma (LUSC)
Because the genetic and epigenetic changes of lung squamous cell carcinoma (LUSC) are very different [4], individualized treatment strategies based on early symptoms of LUSC patients are required
A study exhibited that overexpressing miR-497-5p restrains progression of non-small cell lung cancer (NSCLC) cells [21]
Summary
Few have concerned miR-497-5p in lung squamous cell carcinoma (LUSC). There are approximately 1,600,000 new lung cancer cases annually [1]. Lung cancer makes up 17.09% of cancer cases in China, with a mortality of 24.35%, making it the most common and fatal type of all cancers [2]. Despite the rapid development of therapies, patient’s survival is still poor [3]. Because the genetic and epigenetic changes of lung squamous cell carcinoma (LUSC) are very different [4], individualized treatment strategies based on early symptoms of LUSC patients are required. Detection of biomarkers for LUSC patients has been conducted to enhance patient’s survival [5], but the molecular mechanism related to LUSC has not been studied in depth.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
